Next Gen Biotech

Velasof tablet contains the active components Sofosbuvir and Velpatasvir.  It is used to treat chronic hepatitis C. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV). The treatment duration is often shorter than older treatment regimens. The duration can vary depending on factors such as HCV genotype, previous treatment history, and the presence of liver cirrhosis. Successful treatment with Velasof tablet can significantly reduce liver inflammation and fibrosis caused by HCV infection. By achieving viral eradication, the risk of developing liver cirrhosis, liver failure, and hepatocellular carcinoma (a type of liver cancer) can be substantially reduced.

If you have a known allergy or hypersensitivity to Velasof tablet or any of the components of the medication, you should not take it. The safety and efficacy of sofosbuvir and velpatasvir combination therapy have not been established in children under 18. Its use in the pediatric population is currently limited. It is recommended to use alternative treatment options or adjust the dosage in these cases. 

Velpanat tablet contains the active components Sofosbuvir and Velpatasvir.  It is used to treat chronic hepatitis C. Hepatitis C is a liver infection caused by the hepatitis C virus (HCV). The treatment duration is often shorter than older treatment regimens. The duration can vary depending on factors such as HCV genotype, previous treatment history, and the presence of liver cirrhosis. Successful treatment with Velpanat tablet can significantly reduce liver inflammation and fibrosis caused by HCV infection. By achieving viral eradication, the risk of developing liver cirrhosis, liver failure, and hepatocellular carcinoma (a type of liver cancer) can be substantially reduced.

If you have a known allergy or hypersensitivity to Velpanat tablet or any of the components of the medication, you should not take it. The safety and efficacy of sofosbuvir and velpatasvir combination therapy have not been established in children under 18. Its use in the pediatric population is currently limited. It is recommended to use alternative treatment options or adjust the dosage in these cases.